Clinical Trial Update: A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing VELCADE-melphalan-prednisone vs Daratumumab with VMP in previously untreated multiple myeloma in the Asia-Pacific region has completed; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Alkeran (melphalan)
• DARZALEX (daratumumab)
• Deltasone (prednisone)
• Velcade (bortezomib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED